Over the past decades, significant
progress has been made in targeted
cancer therapy. In precision oncology, molecular profiling of cancer
patients enables the use of targeted cancer therapeutics. However,
current diagnostic methods for molecular analysis of cancer are costly
and require sophisticated equipment. Moreover, targeted cancer therapeutics
such as monoclonal antibodies and small-molecule drugs may cause off-target
effects and they are available for only a minority of cancer driver
proteins. Therefore, there is still a need for versatile, efficient,
and precise tools for cancer diagnostics and targeted cancer treatment.
In recent years, the CRISPR-based genome and transcriptome engineering
toolbox has expanded rapidly. Particularly, the RNA-targeting CRISPR-Cas13
system has unique biochemical properties, making Cas13 a promising
tool for cancer diagnosis, therapy, and research. Cas13-based diagnostic
methods allow early detection and monitoring of cancer markers from
liquid biopsy samples without the need for complex instrumentation.
In addition, Cas13 can be used for targeted cancer therapy through
degrading and manipulating cancer-associated transcripts with high
efficiency and specificity. Moreover, Cas13-mediated programmable
RNA manipulation tools offer invaluable opportunities for cancer research,
identification of drug-resistance mechanisms, and discovery of novel
therapeutic targets. Here, we review and discuss the current use and
potential applications of the CRISPR-Cas13 system in cancer diagnosis,
therapy, and research. Thus, researchers will gain a deep understanding
of CRISPR-Cas13 technologies, which have the potential to be used
as next-generation cancer diagnostics and therapeutics.